title: [The impact of pregnancy-prolonging management on maternal and neonatal morbidity in HELLP syndrome].
abstract: OBJECTIVE
  Until recently, delivery immediately after diagnosing HELLP syndrome was recommended due to the life-threatening risk to mother and child. Prolongation at least until lung maturation is being increasingly considered because of the high rate of premature births characterized by extreme immaturity. We investigated the influence of the time of delivery on maternal and neonatal morbidity at a gestational age of less than 34 + 0 weeks of pregnancy. -
  
  
  METHODS
  The disease course was reevaluated in 37 patients who developed HELLP syndrome (thrombocytes < 100 000/microl, transaminase > 70 U/l, haptoglobin < 0.5 g/l) between 1994 and 1999. An attempt was made to stabilize the mother's condition under therapeutic volume expansion. Pregnancy was terminated with the onset of a renewed HELLP episode. -
  
  
  RESULTS
  HELLP syndrome occurred with an incidence of 1 : 310 births. There were no maternal or neonatal deaths or any severe complications. Prolonging pregnancy until completing drug-induced lung maturity was successful in 16 of 25 patients before the 34(th) week of pregnancy. In the case of immediate delivery with inadequate stabilization, 5 of 9 patients had postpartum complications. A severe RDS occurred in 3 premature babies without drug-induced maturity. -
  
  
  CONCLUSIONS
  If there is no life-threatening risk to the fetus or mother in patients with HELLP syndrome, the objective is the prolongation of pregnancy in a perinatal center until lung maturation. Stabilization is successful in a high percentage of patients under therapeutic volume expansion with optimal monitoring of mother and child.
authors.affiliation: Klinik für Gynäkologie und Geburtshilfe.
authors.forename: A
authors.initials: A
authors.lastname: Hagen
authors.forename: A
authors.initials: A
authors.lastname: Ebert
authors.forename: J
authors.initials: J
authors.lastname: Lange
authors.forename: M
authors.initials: M
authors.lastname: Zemlin
authors.forename: H
authors.initials: H
authors.lastname: Hopp
mesh_terms: D000328:Adult; D001623:Betamethasone / Q000627:therapeutic use*; D002585:Cesarean Section / Q000706:statistics & numerical data*; D019468:Disease Management; D005260:Female; D005440:Fluid Therapy; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D005865:Gestational Age; D005938:Glucocorticoids / Q000627:therapeutic use*; D017359:HELLP Syndrome / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D011225:Pre-Eclampsia / Q000453:epidemiology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D012127:Respiratory Distress Syndrome, Newborn / Q000453:epidemiology*; D012720:Severity of Illness Index
chemical_list: D005938:Glucocorticoids; D001623:Betamethasone